Kinavet CA-1 moves forward to trials

Kinavet CA-1 drew FDA ire last month for bogus marketing claims, with the regulator slamming down on its French drugmaker, AB Science, for boasting off-label uses without seeking approval. The regulator went as far as to say the "evidence that Kinavet is an unapproved new animal drug is particularly compelling" in its warning letter. But the canine cancer drug, intended to treat mast cell tumors, has gone ahead to a Phase III clinical trial in Florida. Article